RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Breakthrough Therapy (China), Orphan Drug (South Korea)

Structure/Sequence

Sequence Code 143885L

Source: *****

Sequence Code 13387733H

Source: *****

Sequence Code 13387743H

Source: *****

Sequence Code 13387747L

Source: *****

Clinical Trials associated with Amivantamab-VMJM

NCT07808359

/ Not yet recruitingPhase 2IIT

Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Who Progressed to First-line Platinum-Based Chemotherapy: APOLO TRIAL (LACOG 2425)

This is a collaborative, multicenter, open-label, Phase 2 clinical trial (APOLO TRIAL / LACOG 2425) designed to evaluate the efficacy, safety, and tolerability of subcutaneous amivantamab monotherapy in adult patients with histologically confirmed recurrent or metastatic penile squamous cell carcinoma (PSCC). Eligible participants must have experienced disease progression on or after receiving at least one platinum-based chemotherapy regimen (with or without immunotherapy). The study allocates participants into two parallel non-randomized cohorts based on their human papillomavirus (HPV) status (HPV-positive and HPV-negative).

Start Date01 Nov 2026

Sponsor / Collaborator-

CTRI/2026/09/118067

/ Not yet recruitingPhase 4

A Phase 4, Open-Label Study to Evaluate Safety of Amivantamab inCombination With Chemotherapy in Indian Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19del or Exon21 L858R Mutations After Progression on Osimertinib - NA

Start Date22 Oct 2026

Sponsor / Collaborator-

NCT07798921

/ Not yet recruitingPhase 1IIT

A Phase 1, Investigator-Initiated, Open-Label, Dose-Escalation Study to Evaluate the Safety, MTD, and Antitumor Activity of JIN-A02 in Combination With Amivantamab in EGFR-Mutant NSCLC Patients Following 3rd-Generation EGFR-TKI Failure

This Phase 1 study will evaluate the safety, maximum tolerated dose, recommended Phase 2 dose, and preliminary antitumor activity of JIN-A02 in combination with amivantamab in participants with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor.
The study includes a dose-escalation phase and a dose-expansion phase. During dose escalation, participants will receive oral JIN-A02 once daily at planned dose levels of 120 mg, 160 mg, or 200 mg in combination with weight-based intravenous amivantamab. Dose escalation will follow a Bayesian optimal interval design, and dose-limiting toxicities during the first 28-day treatment cycle will be used to determine the maximum tolerated dose and recommended Phase 2 dose.
After the recommended Phase 2 dose is determined, additional participants will be enrolled in the dose-expansion phase to further evaluate safety and preliminary antitumor activity. Efficacy assessments will include objective response rate and progression-free survival according to RECIST version 1.1. Exploratory analyses may evaluate changes in EGFR mutations and resistance-associated genomic alterations using circulating tumor DNA collected before and during treatment and at the end of treatment.

Start Date28 Sep 2026

Sponsor / Collaborator

Yonsei University

100 Clinical Results associated with Amivantamab-VMJM

100 Translational Medicine associated with Amivantamab-VMJM

100 Patents (Medical) associated with Amivantamab-VMJM

334

Literatures (Medical) associated with Amivantamab-VMJM

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer

Article

Author: Upton, Elysia ; Hearmon, Natalie ; Procter, Emily ; Nieva, Jorge J. ; Rattigan-Brown, Yanique ; Freeman, Harry ; Lopes, Gilberto de Lima ; Karia, Pritesh

OBJECTIVES:

Novel first-line (1L) combination regimens offer improved efficacy for patients with epidermal growth factor receptor-mutated (EGFRm) locally advanced or metastatic non-small cell lung cancer (NSCLC) versus the standard of care, but their costs have not been comprehensively evaluated. Total and differential costs of 1L osimertinib plus platinum-pemetrexed, intravenous (IV) amivantamab plus lazertinib, and subcutaneous (SC) amivantamab plus lazertinib were estimated from a United States (US) payer perspective.

METHODS:

A cost of care model was developed to assess treatment acquisition, administration, disease management, and adverse event (AE) management costs for osimertinib plus platinum-pemetrexed versus IV and SC amivantamab plus lazertinib for patients with EGFRm NSCLC. A one-year time horizon was chosen to allow for direct treatment comparison; a one-year treatment duration was assumed for treat-to-progression regimen components.

RESULTS:

The total first-year cost per-patient for osimertinib plus platinum-pemetrexed (all-payer perspective: $172,600; private perspective: $253,529; Medicare perspective: $84,926) was over twofold lower than for IV amivantamab plus lazertinib (all-payer perspective: $418,176; private perspective: $618,240; Medicare perspective: $201,441) and for SC amivantamab plus lazertinib (all-payer perspective: $419,718; private perspective: $621,166; Medicare perspective: $201,482). This translated to per-patient cost savings of $245,577; $364,711; and $116,514 for osimertinib plus platinum-pemetrexed versus IV amivantamab plus lazertinib and $247,118; $367,637; and $116,555 versus SC amivantamab plus lazertinib for the all-payer, private, and Medicare perspectives, respectively.

LIMITATIONS:

Limited data availability necessitated cost conversions across payer perspectives and assumptions for select inputs, including specific concomitant medication durations. Additionally, as any payer-negotiated discounts for treatment are confidential, model treatment acquisition costs reflected list prices. These data limitations contributed to uncertainty surrounding model inputs.

CONCLUSIONS:

From a US payer perspective, osimertinib plus platinum-pemetrexed was associated with substantially lower overall costs compared with IV and SC amivantamab plus lazertinib for the 1L treatment of patients with EGFRm locally advanced or metastatic NSCLC.

01 Nov 2026·LASERS IN SURGERY AND MEDICINE

532‐nm KTP Laser Treatment of Epidermal Growth Factor Receptor Inhibitor–Associated Paronychia: A Case Report

Article

Author: Dreifus, Emilee M. ; Chokshi, Aditi ; Eber, Ariel E.

ABSTRACT:

Objectives:

Paronychia is a common and often painful cutaneous adverse event of epidermal growth factor receptor inhibitor therapy that can impair function and quality of life. We report the first known case of amivantamab‐associated paronychia successfully treated with 532‐nm potassium‐titanyl‐phosphate laser.

Materials and Methods:

A 67‐year‐old man with metastatic non‐small cell lung cancer receiving amivantamab developed painful periungual inflammation with pyogenic granuloma‐like changes involving multiple fingers and both great toes after failing multiple topical therapies. A representative lesion on the left fourth digit was selected for treatment and underwent two sessions of 532‐nm KTP laser therapy. Treated and untreated digits were compared for clinical response.

Results:

Following two treatment sessions, the treated digit demonstrated marked improvement in erythema, pain, and friability. Untreated digits remained inflamed and symptomatic, serving as a within‐patient comparator. No adverse events were observed.

Conclusion:

Given its superficial vascular targeting mechanism and broad clinical availability, the 532‐nm KTP laser may represent a practical and effective therapeutic option for refractory EGFRI‐associated paronychia. To our knowledge, this is the first reported case of successful treatment of amivantamab‐associated paronychia with a 532‐nm KTP laser.

01 Nov 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies

Review

Author: Alkhazna, Shahd ; Tojjari, Alireza ; Pourbahrighesmat, Shamimeh ; Saeed, Anwaar

Metastatic colorectal cancer (mCRC) is increasingly managed according to mismatch repair status and actionable molecular alterations. In this structured narrative review, we separately examine mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and microsatellite-stable/mismatch repair-proficient (MSS/pMMR) disease and distinguish established treatments from investigational strategies. In dMMR/MSI-H mCRC, immune checkpoint inhibition is the established first-line standard, with pembrolizumab and nivolumab plus ipilimumab producing durable disease control. In MSS/pMMR mCRC, tumor molecular findings guide targeted therapy. For BRAF V600E-mutant disease, encorafenib plus cetuximab with fluoropyrimidine-based chemotherapy is a first-line standard. HER2-directed therapy with tucatinib plus trastuzumab or trastuzumab deruxtecan and combined KRAS G12C and EGFR inhibition are established after prior treatment but are not approved in the first-line setting. Across MMR subgroups, rare NTRK or RET fusions can confer eligibility for tumor-agnostic TRK or RET inhibition, although CRC-specific cohorts remain small. In previously treated non-MSI-H/dMMR mCRC, STELLAR-303 was the first phase 3 trial to demonstrate a significant overall survival benefit with an immune checkpoint inhibitor-containing regimen, zanzalintinib plus atezolizumab. Other investigational strategies include additional immunotherapy combinations, EGFR-MET bispecific antibody therapy with amivantamab, T-cell-engaging bispecific antibodies, therapeutic cancer vaccines, cellular therapies, and microbiome-directed approaches. For each therapeutic class, we summarize the supporting evidence, define its place in the treatment sequence, and identify the remaining evidence gaps.

403

News (Medical) associated with Amivantamab-VMJM

13 Oct 2026

·www.fiercepharma.com

J&J’s new pharma chief expects Icotyde’s psoriasis launch momentum to repeat across indications

As Johnson & Johnson rode out 2026’s third quarter, leveraging its pharmaceutical segment to navigate medtech headwinds, much of the company’s near-term excitement has turned to IL-23 pill Icotyde, which has been hailed as a potential game changer in plaque psoriasis. J&J has yet to report out discrete sales for Icotyde, or icotrokinra, though the company on Tuesday cited the medicine’s uptake in the U.S. as one driving factor in the 1.3% year-over-year increase in immunology revenue it posted for Q3, during which the unit collectively brought home (PDF) more than $4.2 billion. “We do foresee Icotyde to be one of our biggest assets in innovative medicine, and it’s off to an incredibly great start,” Tom Cavanaugh, worldwide chairman of innovative medicine at J&J, said of the performance on the company’s earnings call Tuesday. Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled through a pool of nearly 9,000 prescribers, Cavanaugh said, noting that the performance is “absolutely tracking better than most all launches in psoriatic disease.” The green light specifically covers the use of Icotyde to treat moderate-to-severe plaque psoriasis in patients ages 12 years and older who are candidates for systemic therapy or phototherapy. At the time of approval, J&J’s then-innovative medicines chief, Jennifer Taubert, opined that Icotyde could set a “new standard” for treatment of the moderate-to-severe form of plaque psoriasis, which is estimated to affect some 8 million people in the U.S. Taubert announced her retirement earlier this year and was formally replaced by Cavanaugh at the innovative medicines helm on Sept. 1. Once-a-day oral Icotyde also boasts a potentially meaningful convenience edge over most other systemic psoriasis treatments, like AbbVie’s Skyrizi or J&J’s sister medicine Tremfya, which often come as injections. Further breaking down the Icotyde launch mix on Tuesday’s call, Cavanaugh explained that around 60% of those new patients are brand-new to a systemic plaque psoriasis treatment, with the remaining 40% comprising a relatively even split between people switching from orals and those coming over from other treatments, which mainly consists of biologics. As the launch continues to play out in psoriasis, Cavanaugh reiterated that many more opportunities lie ahead for Icotyde, which J&J plans to bolster with two upcoming phase 3 readouts in psoriatic arthritis and in a head-to-head against its own Stelara, plus potential expansions further down the line in indications like inflammatory bowel disease. The J&J exec stressed that the company is “expecting similar results with regards to launch performance as we go into those other indications.” Though investors and industry watchers will have to wait a while longer for Icotyde sales to report out, “I’m confident we’re going to be doing that next year, just based on the momentum and the progress that we’re seeing with the launch,” Cavanaugh added later during the call. All told, J&J lifted sales by 5.9% in the third quarter to reach total revenues of $25.4 billion, which analysts at Leerink Partners noted fell in line with consensus. Overall, innovative medicines contributed around $16.8 billion to the haul, up from around $15.6 billion for the period in 2025, while the company’s medtech segment grew 2.5% year over year to a little more than $8.6 billion. Immunology remained the major growth driver overall for the period, primarily thanks to psoriatic and IBD medicine Tremfya, which reported sales of $2.4 billion in Q3, above the estimate put forward by analysts at TD Cowen. Other key J&J products that exceeded TD Cowen’s expectations for the period included Stelara, Carvykti and Caplyta, to name a few, while medications like Rybrevant, Spravato and Darzalex missed the analyst shop’s targets. Meanwhile, buoyed by its recent quarterly performance, J&J raised the lower end of its full-year sales guidance. The company now expects revenue to fall between $101 billion and $101.4 billion, versus its previous forecast of $100.8 billion to $101.4 billion.

Phase 3BiosimilarDrug ApprovalExecutive Change

13 Oct 2026

·www.mddionline.com

J&J Inches Closer to $100 Billion… Will a Medtech Stumble Cloud the Story?

Johnson & Johnson delivered a third-quarter performance on October 13, 2026, that told two very different stories depending on which part of the business you were watching. The pharmaceutical arm, now branded Innovative Medicine, continued its hot streak, while the medical device business once again fell short of where the company wanted it to be. Investors clearly noticed the split. Despite revenue coming in ahead of expectations, J&J shares slipped as much as 4.36% following the announcement, suggesting Wall Street cared more about where the cracks are than where the growth is. The headline numbers were respectable on their face. The company posted $25.4 billion in quarterly revenue, edging past analyst expectations of roughly $25.28 billion, while adjusted earnings of $2.59 per share also topped the consensus estimate of around $2.54. J&J used the results as an opportunity to raise its full-year guidance once again, nudging its reported sales outlook up to a range of $101 billion to $101.4 billion and lifting its adjusted earnings forecast to a midpoint of $11.10 per share. That revenue trajectory would mark a milestone the company has never hit in its 140-year history: crossing the $100 billion mark in annual sales. Still, the quarter wasn't without pain. Reported net earnings cratered to just $210 million, or nine cents per diluted share, a steep drop from the $5.15 billion the company posted in the same period a year earlier. That decline wasn't a sign of operational trouble, but rather the result of roughly $7 billion in special charges tied to talc litigation and recent acquisitions, including Firefly Bio and Sail Biomedicines. Strip those one-time items away, and the underlying business looked considerably healthier, with adjusted net earnings landing at $6.3 billion. The real engine behind J&J's growth story continues to be its drug business. Innovative Medicine sales jumped nearly 8% to $16.76 billion, powered by a handful of standout products. Tremfya, the company's immune disease treatment, was the breakout star of the quarter, with sales soaring 68% to $2.4 billion and comfortably beating analyst projections of about $2.19 billion. That growth matters even more given the backdrop. Stelara, once a reliable blockbuster, has been losing ground to generic competition, with sales falling 54% to $716 million. Tremfya has effectively stepped in to fill that gap, aided by recent approvals in inflammatory bowel disease treatment. Elsewhere in the pharmaceutical portfolio, cancer treatment Darzalex grew about 16% to $4.24 billion, and oncology as a whole led the division with 16.7% operational growth, lifted by newer therapies like Carvykti, Tecvayli, and the recently launched Rybrevant and Lazcluze combination. Medtech told a far less flattering story. Sales rose just 2.5% to $8.6 billion, missing analyst estimates and drawing a notably blunt assessment from Chief Financial Officer Joe Wolk. "Medtech needs to improve quite frankly," Wolk told Bloomberg , acknowledging that the segment underperformed internal expectations. He pointed to a mix of external pressures weighing on the business, including geopolitical tension in the Middle East, budget tightening among European governments, and ongoing pricing pressure in China. In an interview with Reuters , Wolk elaborated on the Middle East dynamic specifically, noting that countries like Kuwait, the UAE, and Saudi Arabia still want premium healthcare systems, "but their budgets now are being resourced and allocated towards defense." Within medtech, cardiovascular products were the bright spot, growing 4.1% on the strength of new electrophysiology platforms, while surgery sales actually declined slightly, hurt by procurement changes in China and the same regional disruptions in the Middle East. One genuine bright spot inside medtech came from the FDA's decision to authorize the company's Ottava robotic surgical system , which J&J is positioning as a legitimate new category in surgical robotics rather than just another entrant into an increasingly crowded field. The system is built around four robotic arms integrated directly into a standard surgical table rather than mounted on separate carts or booms, a design the company says takes up 30% to 50% less operating room space than competing systems. Its initial clearance covers ten general surgery procedures, including gastric bypass and hernia repair, and the company says it has already signed its first commercial customer. Perhaps the biggest strategic headline of the quarter had nothing to do with the current numbers at all. J&J confirmed it intends to spin off its orthopedics business, DePuy Synthes , into a standalone company, with CFO Wolk telling CNBC the company is now targeting mid-2027 for the separation. He made clear the company isn't rushing into a sale just because one is on the table. "We're not cash strapped. We don't have to pursue a deal that maybe is not optimal," Wolk said, adding that J&J has the flexibility to "sit this out for a little bit" before executing the separation on its own timeline. That comment comes against the backdrop of reports that Apollo Global Management has been in talks to acquire the orthopedics unit in a deal that could value it near $20 billion, though Wolk's remarks to Bloomberg suggested the company is leaning toward a straightforward spinoff rather than an outright sale, calling it "the greatest way to create value." Looking at the bigger picture, CEO Joaquin Duato framed the quarter as confirmation that the company's long-term strategy is working, pointing to the Ottava authorization alongside "positive Phase 3 results in multiple myeloma" as proof points. In a separate statement, he said the quarter's performance gives the company "clearer line of sight to double-digit growth by the end of the decade," a target executives say is being driven by internal pipeline execution rather than any assumed wave of acquisitions, even as the company says it remains open to opportunities if they arise. For now, J&J finished the quarter with $17 billion in cash and marketable securities against $45 billion in debt, generated roughly $15 billion in free cash flow over the first nine months of the year, and returned $3.2 billion to shareholders through dividends, continuing a streak that now stretches 55 consecutive years of annual increases. Investors, however, appeared less interested in that stability than in the open questions still hanging over the company. Management has promised more detail on both 2027 guidance and the orthopedics separation at an investor event scheduled for December 8, 2026, leaving the market to wait for clarity on whether medtech can turn itself around and whether the DePuy Synthes exit will unfold on the company's preferred terms.

AcquisitionPhase 3

13 Oct 2026

·healthcare-digital.com

J&J Q3 Earnings: The US$100bn Revenue Goal Remains in Reach

Johnson & Johnson’s Innovative Medicine division was central to its strong Q3 performance. Credit: Johnson & Johnson CFO Joseph Wolk described Johnson & Johnson’s “diversified portfolio” as central to the company’s progress towards its record-breaking revenue target Johnson & Johnson has not tried to hide its 2026 revenue goal. The US$100bn figure – the highest in its 140-year history – has been a target referenced in its earnings reports throughout the year. On 13 October 2026, the pharmaceutical giant published its Q3 earnings report, beating earnings estimates and recording total quarterly sales of US$25.4bn. In doing so, Johnson & Johnson has also raised its full-year guidance to US$101.2bn. Joaquin Duato, Chairman and Chief Executive Officer at Johnson & Johnson. Credit: Johnson & Johnson. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” explains CEO Joaquin Duato . “This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade,” he continues. A diversified portfolio Central to Johnson & Johnson’s continued success in 2026 is, according to Chief Financial Officer Joseph Wolk, the company’s “diversified portfolio.” J&J's portfolio now includes 29 products and platforms generating at least US$1bn in annual sales, spanning its Innovative Medicine and MedTech divisions. J&J Q3 Earnings: Key Facts US$25.4bn – Total sales recorded by Johnson & Johnson in Q3 2026. US$101.2bn – Revised full-year 2026 revenue guidance, taking Johnson & Johnson above its US$100bn milestone target. 68% – Year-on-year sales growth recorded by immunology treatment Tremfya in Q3. US$50bn+ – Johnson & Johnson’s target for annual oncology revenue by 2030, as it aims to become the world’s leading oncology company. 29 – Products and platforms across Innovative Medicine and MedTech generating at least US$1bn in annual sales. The latest addition is Caplyta, which reached US$1bn in year-to-date sales, supported by demand for its use as an adjunctive treatment for major depressive disorder. With this model in place, Joseph is “confident in our ability to exceed US$100bn in revenue for the first time in our company’s 140-year history.” “ We are confident in our ability to exceed US$100bn in revenue for the first time in our company’s 140-year history. ” Joseph Wolk Chief Financial Officer at Johnson & Johnson Innovative Medicines and MedTech divisions Johnson & Johnson’s Innovative Medicine division was central to its strong Q3 performance, generating US$16.8bn in sales. Growth was led by immunology treatment Tremfya, which recorded a 68% increase in sales, alongside contributions from other medicines in the portfolio, including Darzalex and Tecvayli. Oncology also delivered strong results, with sales increasing by 17% overall and Rybrevant sales rising by 64%. Johnson & Johnson aims to become the world’s leading oncology company by 2030, targeting annual revenue of more than US$50bn from the division. Meanwhile, MedTech generated US$8.6bn in sales, driven by electrophysiology and shockwave technologies in Cardiovascular, contact lenses in Vision, and trauma products in Orthopaedics. However, the overall division fell short of the company’s expectations for the quarter. As CEO Joaquin Duato acknowledged during the earnings call, “while we fell short of our expectations for the segment, our conviction in our future direction has not changed.” Joseph similarly highlighted the importance of Innovative Medicine in delivering the quarterly results, saying: “Our third-quarter results were driven by the strength of our Innovative Medicine business. “This performance more than offset headwinds in certain areas of MedTech, enabling us to exceed expectations on both the top and bottom line, while continuing to invest in our pipeline and future growth.” Joseph Wolk, Chief Financial Officer at Johnson & Johnson. Credit: Johnson & Johnson Future direction Looking beyond its immediate financial performance, Johnson & Johnson is positioning its portfolio and pipeline to sustain growth through the end of the decade. In Innovative Medicine, this includes strengthening its oncology capabilities through acquisitions and new clinical developments. Johnson & Johnson completed its US$1bn acquisition of Firefly Bio during the quarter, adding antibody-engineering capabilities to support the development of cancer treatments. MedTech's future growth will depend on bringing new technologies to market and improving performance in areas that fell short of expectations in Q3. Its Ottava surgical robotic system received US FDA De Novo authorisation in July 2026, while its Varipulse Pro cardiovascular platform received approval in Japan during the quarter. Johnson & Johnson - key partners Genmab CEO: Jan van de Winkel | HQ: Copenhagen, Denmark Genmab is a biotechnology company specialising in the development of antibody-based medicines for cancer and other serious diseases. Its collaboration with Johnson & Johnson has produced Darzalex, a key treatment for multiple myeloma, alongside wider work on bispecific antibody technologies. The partnership supports Johnson & Johnson’s oncology portfolio and its ambition to become the world’s leading oncology company by 2030. Legend Biotech CEO : Ying Huang | HQ : Somerset, New Jersey Legend Biotech is a global biotechnology company focused on developing and commercialising cell therapies for cancer. It partners with Johnson & Johnson to develop and commercialise CAR-T treatment Carvykti for patients with multiple myeloma. The collaboration combines Legend Biotech’s cell therapy expertise with Johnson & Johnson’s clinical development and commercial capabilities, strengthening its position in advanced oncology treatments. Company portals Johnson & Johnson Executives Joaquin Duato Chairman of the Board and Chief Executive Officer Joseph Wolk Executive Vice President, Chief Financial Officer

Acquisition

100 Deals associated with Amivantamab-VMJM

External Link

KEGG	Wiki	ATC	Drug Bank
-	Amivantamab-VMJM	L01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
EGFR positive non-small cell lung cancer	Japan	Janssen Pharmaceutical KK	27 Mar 2025
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer	United States	Janssen Biotech, Inc.	19 Aug 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer	United States	Janssen Biotech, Inc.	19 Aug 2024
Non-Small Cell Lung Cancer	Canada	Janssen, Inc.	30 Mar 2022
EGFR ex20ins mutation in non-small cell lung cancer	United States	Janssen Biotech, Inc.	21 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Janssen-Cilag International NV	26 Jan 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Shanghai Johnson & Johnson Pharmaceutical Ltd.	26 Jan 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	China	Cilag AG	26 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	United States	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	China	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	Japan	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	Australia	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	Austria	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	Belgium	Janssen Research & Development LLC	03 Dec 2025
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	Brazil	Janssen Research & Development LLC	03 Dec 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06385080 (OrigAMI-4, ESMO2026)	Phase 1/2	Squamous cell carcinoma of head and neck metastatic First line	29	Amivantamab + pembrolizumab + carboplatin (HPV-unrelated disease)	mtkmynficx(uqmoduriah) = igommoqyxl mucgujrxsc (aqbigozyge, 55 - 92)	Positive	23 Oct 2026
				Amivantamab + pembrolizumab + carboplatin (HPV+ oropharyngeal squamous cell carcinoma (OPSCC))	mtkmynficx(uqmoduriah) = aoruscatjk mucgujrxsc (aqbigozyge )
NCT06120140 (COCOON, ESMO2026)	Phase 2	EGFR-mutated non-small Cell Lung Cancer First line EGFR-mutant	70	SC amivantamab + lazertinib with optimized COCOON DM	mbteiwjpjy(qtirvrdbhc) = bbuwmsacbf xpecukjvij (zllfhhudjw ) View more	Positive	23 Oct 2026
NCT03767075 (Basket of Baskets, ESMO2026)	Phase 2	Solid tumor MET kinase domain mutations/fusion-genes \| MET-amplifications \| EGFR mutations	51	Amivantamab (MET kinase domain mutations/fusion-genes)	fzqvlyglyy(jrtgkucjlt) = zealybrysc adigmblhnl (vmtivnovmp ) View more	Positive	23 Oct 2026
				Amivantamab (MET-amplifications CNG ≥6)	fzqvlyglyy(jrtgkucjlt) = xdgkmwkiuu adigmblhnl (vmtivnovmp ) View more
NCT04487080 (MARIPOSA, ESMO2026)	Phase 3	EGFR-mutated non-small Cell Lung Cancer First line EGFR-mutated	429	Amivantamab-lazertinib	hhombtrhii(tjgajputig) = vfndolkgsr vwdskqfhjj (ozmpyxuude ) View more	Positive	23 Oct 2026
ESMO2026	Not Applicable	EGFR Mutation Lung Cancer	900	Amivantamab	nbzjumzmbr(dlufmtprxr) = Hematologic and vascular events included anemia (31.1%, 99/318), lymphopenia (16.7%, 70/420), and venous thromboembolism (11.3%, 89/790). ttbokdvlxh (utnjvkamjv ) View more	Positive	23 Oct 2026
NCT05601973 (AMAZE-lung, Pubmed \| Lancet Respir Med)	Phase 2	EGFR-mutated non-small Cell Lung Cancer EGFR-mutant	61	LazertinibAmivantamab + LazertinibAmivantamab + LazertinibAmivantamab	cqjsvmbqki(sfhrzwrmsb) = pkwwmafwjp cdbenzhmnz (kemfhjvtmm, 21 - 47) View more	Positive	01 Oct 2026
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Second line \| Third line epidermal growth factor receptor (EGFR) mutated	94	Amivantamab + Carboplatin + Pemetrexed (2L)	cysjminkkd(jdrchutyty) = wqogmscdak vlfrvavcjc (zibzhthdzw, 13.3 - 31.0) View more	Positive	12 Sep 2026
				Amivantamab + Carboplatin + Pemetrexed (3L)	cysjminkkd(jdrchutyty) = uqbfpoqmmb vlfrvavcjc (zibzhthdzw, 3.7 - 21.9) View more
WCLC2026	Not Applicable	EGFR-mutated non-small Cell Lung Cancer EGFR Mutation	18	Amivantamab + Osimertinib	ghufxihhil(qxmnmcoqul) = bjzfczrvak bpkhqvvryo (wjqrtjakqh, 9.7 - 53.5) View more	Positive	12 Sep 2026
				Amivantamab + Osimertinib (exon 21 L858R)	ghufxihhil(qxmnmcoqul) = ylstsoawfa bpkhqvvryo (wjqrtjakqh ) View more
NCT04538664 (PAPILLON, WCLC2026)	Phase 3	Non-Small Cell Lung Cancer First line EGFR Ex20ins	308	Amivantamab-chemotherapy	xthdukctec(hvgxtsdynq) = osqroqtxud gwyusrslhz (mkodvsyxse, 27.0 - 40.8) View more	Positive	12 Sep 2026
				Chemotherapy	xthdukctec(hvgxtsdynq) = dquxmdowjo gwyusrslhz (mkodvsyxse, 24.0 - 32.4) View more
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer	50	Amivantamab+Osimertinib	ggsijklqlt(fpnqasjigt) = Grade 5 ILD was observed in 3 patients (6%), two of whom had prior exposure to immune checkpoint inhibitors (ICIs), including one within 3 months of ICI use tflwvoviwi (cgphwmuxiu ) View more	Positive	12 Sep 2026
				Amivantamab+Osimertinib (2nd or 3rd line)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis